D-BSSE spinoff BioVersys teams up with GSK and successfully reaches clinical milestone
Developing novel antibacterial products for life-threatening infections, BioVersys announced on 5 March that in partnership with the pharma and biotech company GSK they have successfully completed the Innovative Medicines Initiative (IMI2) funded programme and reached a key milestone of delivering a Phase 2-ready tuberculosis clinical candidate. The funding scheme is an EU public private partnership programme.
Find external pagepress release by BioVersys (5 March 2024).
Founded in 2010, external pageBioVersys is a privately owned Swiss pharmaceutical company originating from the D-BSSE Biotechnology Lab of Martin Fussenegger. The company focusses on research and development of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation. With the company’s award-winning TRIC technology, BioVersys can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields. By this means BioVersys addresses the high unmet medical need for new treatments against life threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company's most advanced R&D programmes are in preclinical development for nosocomial infections (hospital infections), and Tuberculosis in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille. In 2020, BioVersys launched its first Phase I clinical trials.
Find all D-BSSE spinoff companies.